Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve using the traditional paradigms of diagnosis and care. The current standard has evolved toward universal HCV screening and treatment, to achieve elimination goals. There are several steps between HCV diagnosis and cure with major barriers along the way. Innovative models of care can address barriers to better serve hardly reached populations and scale national efforts in the United States and abroad. Herein, we highlight innovative models of HCV care that aid in our progress toward HCV elimination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917266 | PMC |
| http://dx.doi.org/10.1002/hep4.1646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies.
Haematologica
September 2025
Department of Gastroenterology, St Vincent's Hospital Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, VIC.
Not available.
View Article and Find Full Text PDFTargeting the ERα DBD-LBD interface with mitoxantrone disrupts receptor function through proteasomal degradation.
Mol Cancer Ther
September 2025
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.
View Article and Find Full Text PDFPersisting Lyme Disease in the Pediatric Population.
Clin Pediatr (Phila)
September 2025
Department of Medicine (Infectious Disease), University of Connecticut Health Center, Boston University Medical Center, Falmouth Hospital, Falmouth, MA, USA.
A total of 101 patients with a clinical picture of persisting Lyme disease seen at the University of Connecticut Health Center and Boston Medical Center were recruited for the study to determine whether persistent infection is the likely cause. Brain SPECT imaging and responses to antibiotic treatments were recorded. Patients had more than 5 symptoms lasting more than 6 months.
View Article and Find Full Text PDFAntibiotic Therapy for Pyelonephritis in the Emergency Department.
Emerg Med Australas
October 2025
Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.
View Article and Find Full Text PDFSevere course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab.
Mult Scler
September 2025
Department of Neurology with Friedrich Baur Institute, LMU University Hospital, LMU Munich, Munich, Germany.
Description of a patient with multiple sclerosis (MS) who underwent immunotherapy with ocrelizumab and suffered a severe course of tick-borne encephalitis (TBE): A 33-year-old man presented with acute cerebellitis with tonsillar herniation. The initial suspected diagnosis of TBE was confirmed after a significant diagnostic delay, likely caused by negative serological testing due to B-cell depletion from ocrelizumab treatment for underlying MS. TBE diagnosis was made using polymerase chain reaction (PCR) and oligo-hybrid capture metagenomic next-generation sequencing (mNGS) of cerebral spinal fluid and brain biopsy samples which yielded a near-full length TBE Virus (TBEV) genome.
View Article and Find Full Text PDF